title: [IgA vasculitis associated with anti-TNF-α inhibitors in a patient with Crohn's disease].
abstract: Anti-TNF-α inhibitors have been widely used in the treatment of inflammatory bowel disease. Although they have good clinical efficacy and tolerance, they remain a matter of concern because they cause drug-induced autoimmune disorders as side effects. Here, we report a case of a patient with Crohn's disease who developed IgA vasculitis after infliximab and adalimumab treatment. A 17-year-old male with Crohn's disease who had received scheduled infliximab treatment for the preceding 19 months complained of purpura on his lower limbs. He was diagnosed with infliximab-induced IgA vasculitis. Switching infliximab to adalimumab resulted in rapid improvement of the condition. However, 21 months after switching to adalimumab, his purpura recurred. Drug-induced IgA vasculitis is a rare complication caused by infliximab and adalimumab; however, diagnosis in the early phase and appropriate management of patients receiving anti-TNF-α inhibitors is critical to a successful patient outcome.
authors.affiliation: Department of Internal Medicine, Saiseikai Toyama Hospital.
authors.forename: Jun
authors.initials: J
authors.lastname: Nishikawa
authors.forename: Ayumu
authors.initials: A
authors.lastname: Hosokawa
authors.forename: Momoko
authors.initials: M
authors.lastname: Akashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mihara
authors.forename: Sohachi
authors.initials: S
authors.lastname: Nanjo
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yoshita
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ando
authors.forename: Shinya
authors.initials: S
authors.lastname: Kajiura
authors.forename: Haruka
authors.initials: H
authors.lastname: Fujinami
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000293:Adolescent; D001706:Biopsy; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D000069285:Infliximab / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D012008:Recurrence; D014657:Vasculitis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
chemical_list: D007070:Immunoglobulin A; D000069285:Infliximab; D000068879:Adalimumab